Press Releases



October 17, 2017 - Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
October 12, 2017 - Optinose Announces Pricing of Initial Public Offering
September 18, 2017 - Optinose Announces FDA approval of XHANCE™ (fluticasone propionate) nasal spray for the treatment of nasal polyps
May 9, 2017 - OptiNose Raises $37 Million in Series D Funding Led by Fidelity
February 9, 2017 - Michael F. Marino Joins OptiNose as Chief Legal Officer
January 31, 2017 - OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
January 27, 2017 - OptiNose Appoints Keith Goldan as Chief Financial Officer
October 7, 2016 - Tom Gibbs Joins OptiNose™ as Chief Commercial Officer
September 19, 2016 - New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients
September 16, 2016 - OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis (CRS) with and without Nasal Polyps